Sign in

CIK 0001714899 · Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
463872213
Phone
(650) 866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. SC 13G/A Stake Amended Statement of Ownership
  2. 4 Open-market sale COO and Secretary sold 7,500 shares at an average $19.08 ($143,089)
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. SC 13G Stake Amended Statement of Ownership
  8. SC 13G/A Stake Amended Statement of Ownership
  9. 4 Open-market sale Chief Medical Officer sold 17,500 shares at an average $18.72 ($327,589)
  10. 4 Open-market sale President and CEO sold 18,334 shares at an average $18.72 ($343,300)
  11. 4 Open-market sale COO and Secretary sold 7,500 shares at an average $20.37 ($152,750)
  12. 4 Open-market sale Chief Medical Officer sold 14,502 shares at an average $19.55 ($283,506)
  13. 4 Open-market sale President and CEO sold 18,333 shares at an average $19.43 ($356,288)
  14. 8-K Event Other events
  15. 4 Open-market sale COO and Secretary sold 7,500 shares at an average $20.40 ($153,000)
  16. 4 Open-market sale Chief Medical Officer sold 17,500 shares at an average $18.45 ($322,834)
  17. 4 Open-market sale President and CEO sold 18,333 shares at an average $18.43 ($337,938)
  18. 10-Q/A Report 10-Q/A
  19. 4 Open-market sale Chief Medical Officer sold 17,500 shares at $18.07 ($316,157)
  20. 8-K Event Other events

Page 34 of 40 · 789 filings